Chances to Survive Breast Cancer Increase With New Drug — Cancer Cure

Henrietta Strickland
Июня 7, 2019

The results were presented at the annual meeting of the American Society of Clinical Oncology in Chicago Saturday and will be published Tuesday in the New England Journal of Medicine.

The rate of mortality was 29% less than when the patients, all under the age of 59 and pre-menopausal were assigned with a random control experiment.

"This trial was unique because it looks at younger women who haven't gone through menopause", said Hurvitz in a statement "This is an important group to study since advanced breast cancer is the leading cause of cancer death in women 20 to 59, and the vast majority of breast cancer is hormone-receptor positive".

Seventy percent of the women who took the combination therapy were alive after 42 months according to the findings, compared to 46% for women who were treated with only the hormone therapy and a placebo. "You actually can get synergy, or a better response, better cancer kill, by adding one of these cell-cycle inhibitors" on top of the hormone-blocking therapy, said Hurvitz.

Kisqali, which is taken as a tablet, is one of a few newer breast cancer drugs on the market called CDK4/6 inhibitors, a type of drug that works by blocking two proteins that help cancer cells grow and divide.

The treatment is way less toxic than the typical chemotherapy because it targets the cancerous cells more selectively, makes their ability of multiplication block.

According to previous studies, the incidence of advanced breast cancer grew two percent per year in the U.S. between 1978 and 2008 for women between age 20 to 39. In the United States, breast cancer is the most common cancer in women.

Even though the patients had advanced disease, the drug stalled the disease for an average of eight months.

A pill is administered daily for 21 days followed by seven days off to allow the body time to recover since two-thirds of patients have a moderate to a severe drop in white cell count.

But, she added, "the majority of patients in the USA with commercial insurance will pay $0 per month for their Kisqali prescription". "The use of ribociclib as a frontline therapy significantly prolonged overall survival, which is good news for women with this awful disease".

The study may also stimulate further research into whether the combination of ribociclib and other types of drug that are now not approved by the National Institute for Health and Care Excellence could help another class of breast cancer patients - those who have received prior hormone therapy. Burstein is with the Dana-Farber Cancer Institute in Boston. That is around 24 percent better than the survival rate for women who only undergoes endocrine therapy. A new global clinical trial is now underway.

Other reports by

Discuss This Article